These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 21565353)

  • 1. Analysis of HIV-1 fusion peptide inhibition by synthetic peptides from E1 protein of GB virus C.
    Sánchez-Martín MJ; Hristova K; Pujol M; Gómara MJ; Haro I; Alsina MA; Busquets MA
    J Colloid Interface Sci; 2011 Aug; 360(1):124-31. PubMed ID: 21565353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biophysical investigations of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide.
    Sánchez-Martín MJ; Urbán P; Pujol M; Haro I; Alsina MA; Busquets MA
    Chemphyschem; 2011 Oct; 12(15):2816-22. PubMed ID: 21905195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physicochemical characterization of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide: interaction with model membranes.
    Sánchez-Martín MJ; Cruz A; Busquets MA; Haro I; Alsina MA; Pujol M
    Int J Pharm; 2012 Oct; 436(1-2):593-601. PubMed ID: 22868231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.
    Herrera E; Gomara MJ; Mazzini S; Ragg E; Haro I
    J Phys Chem B; 2009 May; 113(20):7383-91. PubMed ID: 19402654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of E1(64-81) hepatitis G peptide on the in vitro interaction of HIV-1 fusion peptide with membrane models.
    Sánchez-Martín MJ; Busquets MA; Girona V; Haro I; Alsina MA; Pujol M
    Biochim Biophys Acta; 2011 Sep; 1808(9):2178-88. PubMed ID: 21672514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surface behavior of peptides from E1 GBV-C protein: Interaction with anionic model membranes and importance in HIV-1 FP inhibition.
    Galatola R; Cruz A; Gómara MJ; Prat J; Alsina MA; Haro I; Pujol M
    Biochim Biophys Acta; 2015 Feb; 1848(2):392-407. PubMed ID: 25450346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the inhibition capacity of an 18-mer peptide domain of GBV-C virus on gp41-FP HIV-1 activity.
    Haro I; Gómara MJ; Galatola R; Domènech O; Prat J; Girona V; Busquets MA
    Biochim Biophys Acta; 2011 Jun; 1808(6):1567-73. PubMed ID: 21377446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.
    Herrera E; Tenckhoff S; Gómara MJ; Galatola R; Bleda MJ; Gil C; Ercilla G; Gatell JM; Tillmann HL; Haro I
    J Med Chem; 2010 Aug; 53(16):6054-63. PubMed ID: 20718496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatty acids can substitute the HIV fusion peptide in lipid merging and fusion: an analogy between viral and palmitoylated eukaryotic fusion proteins.
    Lev N; Shai Y
    J Mol Biol; 2007 Nov; 374(1):220-30. PubMed ID: 17919659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes.
    Pritsker M; Rucker J; Hoffman TL; Doms RW; Shai Y
    Biochemistry; 1999 Aug; 38(35):11359-71. PubMed ID: 10471286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposome destabilization induced by synthetic lipopeptides corresponding to envelope and non-structural domains of GBV-C/HGV virus. Conformational requirements for leakage.
    Fernández-Vidal M; Rojo N; Herrera E; Gómara MJ; Haro I
    Biophys Chem; 2008 Jan; 132(1):55-63. PubMed ID: 17988786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of FP-HIV activity by peptide sequences of GB virus C: a biophysical approach.
    Domènech O; Ortiz A; Pujol M; Haro I; Muñoz M; Alsina MA; Prat J; Busquets MA; Girona V
    Biochim Biophys Acta; 2014 May; 1838(5):1274-80. PubMed ID: 24530897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic peptides derived from an N-terminal domain of the E2 protein of GB virus C in the study of GBV-C/HIV-1 co-infection.
    Fernández L; Chan WC; Egido M; Gómara MJ; Haro I
    J Pept Sci; 2012 May; 18(5):326-35. PubMed ID: 22438139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of fusion peptides from HIV gp41 with membranes: a time-resolved membrane binding, lipid mixing, and structural study.
    Buzón V; Padrós E; Cladera J
    Biochemistry; 2005 Oct; 44(40):13354-64. PubMed ID: 16201760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cyclic GB virus C derived peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1.
    Galatola R; Vasconcelos A; Pérez Y; Cruz A; Pujol M; Alsina MA; Gómara MJ; Haro I
    Eur J Med Chem; 2014 Oct; 86():589-604. PubMed ID: 25218908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.
    Gómara MJ; Sánchez-Merino V; Paús A; Merino-Mansilla A; Gatell JM; Yuste E; Haro I
    Biochim Biophys Acta; 2016 Jun; 1860(6):1139-48. PubMed ID: 26905802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection.
    Yu H; Tudor D; Alfsen A; Labrosse B; Clavel F; Bomsel M
    Retrovirology; 2008 Oct; 5():93. PubMed ID: 18925934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural analysis and assembly of the HIV-1 Gp41 amino-terminal fusion peptide and the pretransmembrane amphipathic-at-interface sequence.
    Lorizate M; de la Arada I; Huarte N; Sánchez-Martínez S; de la Torre BG; Andreu D; Arrondo JL; Nieva JL
    Biochemistry; 2006 Dec; 45(48):14337-46. PubMed ID: 17128972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mode of interaction between the HIV-1-neutralizing monoclonal antibody 2F5 and its epitope.
    Fiebig U; Schmolke M; Eschricht M; Kurth R; Denner J
    AIDS; 2009 May; 23(8):887-95. PubMed ID: 19414989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the interacting domain of the HIV-1 fusion peptide with the transmembrane domain of the T-cell receptor.
    Cohen T; Pevsner-Fischer M; Cohen N; Cohen IR; Shai Y
    Biochemistry; 2008 Apr; 47(16):4826-33. PubMed ID: 18376816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.